Advanced Breast Cancer Drug Fails Key Clinical Trial Days After Approval

The SERENA-4 trial included 1,371 patients with previously untreated advanced hormone receptor-positive, HER2-negative breast cancer. Researchers compared camizestrant plus Ibrance with Ibrance and...